GLOBAL IN VITRO LUNG MODEL MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)
In vitro lung models are experimental systems that aim to mimic the physiological and anatomical properties of the human lungs. They are widely used in drug discovery, toxicity testing, and studying lung diseases. By utilizing human lung cells and tissues grown outside of the body, these models offer a relatively affordable and effective alternative to animal testing. They also provide a more realistic and controllable environment to study human lung biology and disease pathology compared to animal models. Going forward, advances in tissue engineering, microfluidics, and other technologies are expected to help develop highly complex 3D lung models that can better recreate the in vivo lung microenvironment.
Market Dynamics:
The global in vitro lung model market is driven by factors such as rising drug R&D investments by pharmaceutical companies, stringent regulations regarding animal testing, and increasing prevalence of respiratory diseases. However, high costs associated with developing advanced 3D lung models and shorter shelf life of tissues are expected to restrain the market growth. Meanwhile, ongoing advances in microfabrication and 3D bioprinting technologies are projected to create significant opportunities for manufacturers to develop next-gen biomimetic models. The market is also anticipated to gain from growing focus on developing personalized lung models incorporating individual patient-derived cells and tissues.
On the other hand, rising research and development by market players is further expected to propel the market growth over the forecast period. For instance, on March 6, 2023, AlveoliX AG, a biotechnology company, published a study in Frontiers Media S.A., a peer-reviewed, open access, scientific journals, entitled “A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip” for various respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and fibrosis, due to limited number of U.S. Food and Drug Administration, approved inhaled drugs for these serious lung conditions has led to a shift from in vivo towards the use of alternative in vitro human-relevant models to better predict the toxicity of inhaled particles in preclinical research.
Key features of the study:
Detailed Segmentation:
Table of Contents
*Browse 35 market data tables and 30 figures on “Global In Vitro Lung Model Market” - Global forecast to 2030
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients